Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07465666 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

Study acronym: REAL-HTN
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Jun 1, 2027 → Aug 2, 2027
See other at-risk trials from Novartis

Record History

  1. Start date pushed from Sep 15, 2026 to Sep 30, 2026 Primary and study completion dates: Aug 15, 2027 to Aug 31, 2027 · Eligibility criteria expanded, about 11 words · Secondary endpoints: details revised at 1 of 3 entries Show 3 more changesShow less
    • Primary and study completion dates: Aug 15, 2027 to Aug 31, 2027
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Start date: Aug 15, 2026 to Sep 15, 2026v5
  3. Primary and study completion dates: Aug 2, 2027 to Aug 15, 2027 Start date: Aug 1, 2026 to Aug 15, 2026v4 Show 1 more changeShow less
    • Start date: Aug 1, 2026 to Aug 15, 2026
  4. Start date: Jun 1, 2026 to Aug 1, 2026 Primary and study completion pushed from Jun 1, 2027 to Aug 2, 2027v3 Show 1 more changeShow less
    • Primary and study completion pushed from Jun 1, 2027 to Aug 2, 2027
  5. Start date: Apr 1, 2026 to Jun 1, 2026 Primary and study completion pushed from Apr 18, 2027 to Jun 1, 2027 · Eligibility criteria expanded, about 33 words · Secondary endpoints revised (3)v2 Show 3 more changesShow less
    • Primary and study completion pushed from Apr 18, 2027 to Jun 1, 2027
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 31 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Trial Details
NCT Number NCT07465666
Lead Sponsor Novartis Pharmaceuticals
Conditions Hypertension
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov